A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia

Abstract

Cardiovascular disease (CVD), including heart disease and stroke, continues to be the leading cause of death worldwide. Patients with mental health disorders, including schizophrenia (SCZ) are known to have an increased risk for CVD. Given the association with metabolic syndrome, patients with SCZ are often prescribed metformin and statins but its impact remains unsatisfactory. The use of aspirin (ASA) to decrease cardiovascular risk in the general population has been thoroughly investigated and clear guidelines are currently in place. Since adjuvant treatment with ASA could possibly decrease CVD risk and mortality in SCZ, we conducted a systematic review of the literature to determine the state of the current literature on this subject. Our systematic review points to gaps in the literature on CVD prevention in SCZ and illustrates an obvious need for further research. Although several studies have shown increased CVD risk in SCZ, to date, no research has been conducted on the utilization of CVD preventative treatment such as ASA for SCZ.

Exploration on the potential efficacy and mechanism of methyl salicylate glycosides in the treatment of schizophrenia based on bioinformatics, molecular docking and dynamics simulation

“…As we know, anti-inflammatory and immunomodulatory therapeutic strategies have been a major focus in the treatment of SCZ in recent years 11 , 79 , 80 . As a classic non-steroidal anti-inflammatory drug, aspirin has also attracted much attention in psychiatric treatment, and its efficacy is still in the process of evaluation and practice, indicating that the components have high application prospects and research value 7 , 8 , 10 . In this study, MSTG-A, MSTG-B and Gaultherin have obvious potential efficacy and advantages in the treatment of SCZ.…”

“…It is used in the treatment of acute and chronic rheumatic diseases, the early treatment and prevention of cardiovascular diseases, and the cerebrovascular diseases. Aspirin has properties that inhibit the proinflammatory state of the brain 9 , and may reduce the risk of cardiovascular disease and mortality in patients with SCZ 10 . Drugs are being investigated for their role as adjunctive or monotherapy in the treatment of SCZ.…”

Treatment of 95 post-Covid patients with SSRIs

“…Because SSRIs inhibit the reuptake of serotonin in platelets, they prolong clotting time and could theoretically dissolve microclots. 75,76 The two patients with factor V Leiden thrombophilia responded well and moderately, respectively. This could mean that the anticoagulant effect of SSRIs -assuming that microclots played a role in these patients -might contribute to their response.…”